Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
How do you image when using DIBH with breast treatment?
Do you use portal or orthogonal imaging or both?
Answer from: Radiation Oncologist at Community Practice
For patients undergoing DIBH we use standard portal imaging only.
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
VisionRT/OSMS daily with weekly standard ports
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
We use daily imaging of one tangential field . To minimize dose and exposure we only take one image of actual field and not double exposure with open field
Sign in or Register to read more
5160
5179
5178
Related Questions
How would you treat a young breast cancer patient with limited nodal involvement and an isolated sternal oligometastasis at diagnosis?
Does radiation therapy (ex. to the breast) in patients with CDK4 mutations increase the risk of developing melanoma?
Do you consider chest wall constraints when treating with 5-fraction APBI?
When utilizing hypofractionated radiotherapy in the post mastectomy setting, are the nodal regions dose painted to a different dose or the same dose as the chest wall/reconstructed breast?
How do you optimally set a patient up for breast radiation therapy if you don't have access to a breast board or wing board?
When should the dissected axilla (levels I-II) be included when delivering RNI?
When treating early stage breast cancer with adjuvant RT, what risk factors would lead you to include the level 1 and 2 axilla in patients with pN0(i+) disease?
In a patient with cardiac comorbidities, who meets ASTRO APBI criteria other than a positive margin, would you offer APBI in an attempt to reduce cardiac dose?
How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?
For patients between 40-49 years old who undergo lumpectomy, how do you choose between offering PBI per the updated PBI guidelines or boosting based on boost guidelines?